Abstract: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.

Abstract: Fluorescent labeled reporter compounds having a modified cyanine dye that is coupled to a nucleotide derivative through a linker are disclosed. The compounds are useful for nucleic acid sequence analysis. The fluorescent labeled reporter compounds are ring-locked cyanine dyes that are coupled to a nucleotide derivative, such as a modified DNA base, through a linker. These fluorescent labeled reporter compounds can be used as DNA chain-terminators in DNA synthesis to generate DNA fragments that are fluorescently-labeled at the 3?-terminal end of the DNA fragment.

Abstract: The invention relates to a method of preparing nitrogen macrocycles having formula (I). The inventive method comprises a step involving the reaction of compounds (II) and (III) in order to form a compound having formula (IV). Said compound is subsequently made to react with a compound having formula (V) in order to form a compound having formula (VI).

Abstract: This invention relates to compounds of the formula (I) in which R1, R2, R3, X and Q are as defined above and their use as PDE IV inhibitors.

Abstract: An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the

Abstract: Amine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Abstract: Stable carbene ligands are provided having a carbene center flanked by a quaternary carbon and an amino group, and having utility in the preparation of various transition metal complexes.

Abstract: Selected chlorohydrin and cationic compounds containing nitroxide or hydroxylamine moieties are effective in stabilizing pulp or paper, especially pulp or paper containing lignin, against yellowing and discoloration due to the adverse effects of light. These compounds are added at various points in the paper-making process, especially at the wet ends, making the need for water soluble or water dispersible materials having high affinity for pulp or paper essential. This performance is often further enhanced by the presence of one or more coadditives selected from the group consisting of the UV absorbers, the polymeric inhibitors, the nitrones, the fluorescent whitening agents and metal chelating agents. Combinations of hydroxylamines or their salts, benzotriazole or benzophenone UV absorbers and a metal chelating agent are particularly effective.

Abstract: N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

Abstract: In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula (V), which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula (IX, IXa).

Abstract: One aspect of the present invention relates to quinine-based and quinidine-based catalysts. Another aspect of the invention relates to a method of preparing a derivatized quinine-based or quinidine-based catalyst comprising 1) reacting quinine or quinidine with base and a compound that has a suitable leaving group, and 2) converting the ring methoxy group to a hydroxy group. Another aspect of the present invention relates to a method of preparing a chiral, non-racemic compound from a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral ketone, comprising the step of: reacting a prochiral electron-deficient alkene or azo compound or prochiral aldehyde or prochiral ketone with a nucleophile in the presence of a catalyst; thereby producing a chiral, non-racemic compound; wherein said catalyst is a derivatized quinine or quinidine.

Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.

Abstract: An oxadiazole compound and process of making same, is represented by Formula I: wherein R1 represents a substituted or unsubstituted straight, branched, or cyclo-alkyl group having at least two carbon atoms, and R2 represents an alkyl, aryl, or heteroaryl group.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof.

Abstract: Polyene oxazoles of the following formula wherein R3 is selected from H and methyl, are disclosed. Such compounds, and pharmaceutically acceptable salts thereof, may be used in the inhibition of tumor cell growth. The polyene oxazoles and their pharmaceutically acceptable salts may be formulated as pharmaceutical compositions with pharmaceutically acceptable carriers for use in the inhibition of tumor cells. The polyene oxazoles may be obtained from strains of Streptomyces sparsogenes, such as strain 022 having deposit number IDAC 270504-04.

Abstract: Provided is a novel method of making 2-butyl-3-[[2?(1-trityl-1H-tetrazol-5-yl)biphen-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-ene-4-one, which can be converted to irbesartan. Also provided are methods of making irbesartan.

Abstract: A novel composition comprises a compound of Formula 1 the pharmaceutically acceptable salts, hydrates, solvates, crystal forms, diastereomers, prodrugs, or mixtures thereof. The composition is of particular utility in the treatment of kinase-implicated disorders.

Abstract: The present invention relates to a process for the preparation of (3-cyano-1H-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone and salts thereof, characterised in that an indole ester of the formula II in which R is as defined in Claim 1, is converter into 3-cyano-1H-indole-7-carboxylic acid via steps (1) to (4) according to Claim 1, and this is reacted with 1-[2-(4-fluorophenyl)ethyl]piperazine of salts thereof to give the product.

Abstract: Compounds of formula I and a process for the preparation of such compounds are disclosed.

Abstract: A compound of the general formula (I) or (II) wherein X is O, NR4 or S and R1-R8 are as defined in the specification

Abstract: The present invention provides, according to an aspect thereof, a novel process for the preparation of dronedarone [1] and pharmaceutically acceptable salts thereof. According to a preferred embodiment, the process comprises N-acetylating of p-anisidine or p-phenetidine with acetic anhydride, reacting of the obtained N-(4-alkoxyphenyl)acetamide with 2-bromohexanoyl chloride or bromide in the presence of aluminum chloride or bromide to obtain N-[3-(2-bromohexanoyl)-4-hydroxyphenyl]acetamide [6a], converting the compound [6a] into 2-butyl-5-benzofuranamine hydrochloride [12a] and subsequently converting [12a] into [1] or pharmaceutically acceptable salts thereof. In accordance with another aspect of this invention, there are provided novel intermediates, inter alia the novel compounds [6a] and [12a]. The novel intermediates of the present invention are stable, solid compounds, obtainable in high yields, which can be easily purified by crystallization and stored for long periods of time.

Abstract: A method for purifying hydroxyalkyl amide of residual alkanolamine by using nonpolar solvent, an acidic pH, salt solutions and an elevated temperature.

Abstract: Provided is a method for producing an optically active compound, in more detail, for producing an optically active compound by asymmetric hydrogenation in a high yield and asymmetric yield. The present invention also provides a catalyst for asymmetric synthesis for the above production method, especially a catalyst for asymmetric hydrogenation, containing a transition metal complex. Further, the present invention provides a new diphosphine compound useful as a ligand of the above transition metal complex and a new transition metal complex containing the above diphosphine compound. The present invention relates to a diphosphine compound represented by the following formula (1): a transition metal complex using the compound, a catalyst for asymmetric synthesis comprising the above transition metal complex and a method for producing an optically active compound using the above catalyst for asymmetric synthesis.

Abstract: A process is provided for the manufacture of highly sulfurized metal dithiocarbamates, such as molybdenum dithiocarbamate. A metal source source, water and a reagent amine are heated under pressure with carbon disulfide.

Abstract: Diene-bis-aquo-rhodium(I) complex of the general formula [Rh(diene)(H2O)2]X where diene is a cyclic diene and X is a noncoordinating anion.

Abstract: The invention relates to a process for preparing arylvinyl halides and sulphonates and arylalkynes by reacting haloaromatics or aryl sulphonates with vinyl halides or sulphonates in the presence of a palladium catalyst and a base and, if appropriate, subsequent elimination.

Abstract: The present invention relates to an interfacial method of preparing ester-substituted diaryl carbonates. The method includes the steps of: forming a reaction mixture comprising phosgene, an ester-substituted phenol, an organic solvent, and a catalyst selected from the group consisting of a tertiary amine catalyst and a phase transfer catalyst, said reaction mixture having an organic phase and an aqueous phase, wherein said aqueous phase has a brine strength; allowing the reaction mixture to react wherein during the reaction, (i) the aqueous phase has a pH, and the pH is adjusted, if necessary, by the addition of an alkali metal hydroxide solution in amounts such that the pH is greater than or equal to 9.

Abstract: This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Abstract: Provided are an adamantane derivative characterized by having a structure represented by Formula (I) and a process for producing an adamantane derivative in which n is 0 in Formula (I) described above, wherein an adamantane compound is reacted with a nitrile compound and then with acid halide or acid anhydride of (meth)acrylic acids.

Abstract: The invention relates to a method of producing fatty acid monoesters and polyhydroxylic alcohols by means of transesterification between a polyhydroxylic alcohol and a compound that is selected from a fat of animal origin, a fat of vegetable origin, and a fatty acid methyl ester. The invention is characterised in that the transesterification reaction is performed in the presence of basic solid catalysts, said basic solids being oxides that are selected from mixed oxides of one or more monovalent metals and one or more trivalent metals, mixed oxides of one or more divalent metals and one or more trivalent metals, and mixtures of same.

Abstract: The present invention relates to 3?,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-oic acid methanol solvate, its use in medicine and processes for its preparation.

Abstract: The present invention discloses a process for producing an aliphatic dicarboxylic acid compound, which comprises oxidizing, with a nitrite or a nitrate in the presence of trifluoroacetic acid, an alicyclic secondary alcohol compound or an alicyclic ketone compound, in each of which at least one methylene group is bonded to the carbon atom having hydroxyl group bonded thereto or the carbon atom as a member of carbonyl group, wherein the reaction is conducted in the presence of water of 5 mass % or less relative to 100 mass % of the total of the trifluoroacetic acid and the water.

Abstract: The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor.

Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Abstract: Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein the variables G, L, A, W, E, R2, R3, R4, R5, RN, and Rc are defined herein. These compounds interact with and inhibit the activity of the enzyme beta-secretase. These compounds are therefore useful in treating Alzheimer's disease and other similar diseases. Pharmaceutical compositions and methods of treatment of these diseases are also disclosed.

Abstract: Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.

Abstract: The present invention relates to a process for the production of mixtures of di- and polyamines of the diphenylmethane series (MDA) containing less than 1,000 ppm of water and less than 200 ppm of aniline by reaction of aniline and formaldehyde in the presence of acid catalysts and subsequent separation of the acid catalyst and subsequent distillative separation of water and aniline in an at least a two-stage distillation including a flash evaporation and subsequent cooling.

Abstract: The present invention relates to a process for reacting epoxides with an initiator compound in the presence of a double metal cyanide compound as a catalyst, said process having a shortened induction period, and the double metal cyanide compound being activated by adding the epoxide to a mixture of double metal cyanide compound and initiator compound at an internal reactor pressure of less than 1 bar, and also to the polyethers themselves obtainable by such a process.

Abstract: The invention relates to a process for simultaneously performing two chemically successive reactions in a loop reactor, specifically reaction I) an optionally catalyzed equilibrium reaction between high-boiling liquid reactants, in which essentially one high boiler is formed as an intermediate and at least one low boiler as a by-product, and reaction II) a substantially diffusion-controlled reaction in which the liquid intermediate is reacted with at least one gaseous reactant to give the end product, wherein reactions (I) and (II), optionally after a start phase, are allowed to proceed simultaneously in the same apparatus, specifically loop reactor, and the loop reactor has a connectable gas-liquid circulation system coupled via an ejector mixing nozzle, in which circulated liquid phase is mixed in the ejector mixing nozzle with newly supplied gaseous reactant of reaction (II) (6) and/or gaseous reactant of reaction (II) aspirated by means of the ejector from the reactor via a connectable condenser (5), and

Abstract: A process for cleaving an oxidation product comprising s-butyl benzene hydroperoxide and/or cumene hydroperoxide which reduces the production of non-recoverable by-products from dimethylbenzyl alcohol (DMBA) and ethyl methyl benzyl carbinol (EMBA).

Abstract: Methods for preparing 2,3,5,6-tetrafluorodimethylolbenzene, an intermediate for the preparation of pyrethroids, are disclosed. A method for preparing 2,3,5,6-tetrafluorodimethylolbenzene includes the reduction of tetrafluoroterephthalate. Various reduction processes are disclosed, which are simple and safe and can afford the product in high yield and purity. Processes for preparing tefluthrin from 2,3,5,6-tetrafluorodimethylolbenzene, by halogenation, hydrogenation, and esterification, are also disclosed.

Abstract: The invention provides an economic process for the manufacture of the hydrofluorocarbon 1,1,3,3,3-pentafluoropropene (HFC-1225zc). HFC-1225zc can be made from the dehydrochlorination of 1-chloro-1,1,3,3,3-pentafluoropropane (HCFC-235fa). Alternatively, HFC-1225zc can also be made from the dehydrofluorination of 1,1,1,3,3,3-hexafluoropropane (HFC-236fa). HFC-1225zc) is a compound that has the potential to be used as a low Global Warming Potential refrigerant, blowing agent, aerosol propellant, or solvent.

Abstract: A method for the selective reduction of an aromatic compound. The present invention provides a method for pre-venting the reduction of at least one halogen substituted aromatic ring of an aromatic compound, while allowing the reduction of at least one functional group on the aromatic compound. In the present invention at least one hydroxyl group is placed on the at least one halogen substituted aromatic ring to be protected from reduction. The aromatic compound is then reacted with at least one alkali metal in at least one nitrogen containing base and at least one alcohol at a ratio of the alcohol to the nitrogen containing base at which the aromatic ring with the hydroxyl group is protected from reduction, while the desired functional group is reduced.

Abstract: This invention provides an attrition resistant metalloaluminophosphate molecular sieve catalyst composition, methods of making the catalyst composition and processes for using the catalyst composition. The metalloaluminophosphate molecular sieve catalyst composition is highly attrition resistant in dried as well as fully calcined forms.

Abstract: An FCC process for obtaining light olefins comprises contacting a hydrocarbon feed stream with blended catalyst comprising regenerated catalyst and coked catalyst. The catalyst has a composition including a first component and a second component. The second component comprises a zeolite with no greater than medium pore size wherein the zeolite comprises at least 1 wt-% of the catalyst composition. The contacting occurs in a riser to crack hydrocarbons in the feed stream and obtain a cracked stream containing hydrocarbon products including light olefins and coked catalyst. The cracked stream is passed out of an end of the riser such that the hydrocarbon feed stream is in contact with the blended catalyst in the riser for less than or equal to 2 seconds on average. The hydrocarbon products including light olefins are separated from the coked catalyst. The first portion of the coked catalyst is passed to a regeneration zone in which coke is combusted from the catalyst to produce a regenerated catalyst.

Abstract: A process for cracking a heavy hydrocarbon feedstock containing non-volatile components and/or coke precursors, wherein a stripping agent is added to the feedstock to form an enhanced hydrocarbon blend which is thereafter separated into a vapor phase and a liquid phase by flashing in a flash/separation vessel, separating and cracking the vapor phase, and recovering cracked product. The stripping agent increases vaporization of the volatile fraction of the heavy hydrocarbon increasing the maximum feedrate capacity of the furnace.

Abstract: Disclosed is an elongated absorbent article including a liquid absorbent layer. In a region where the liquid absorbent layer is present, compressed grooves are disposed to extend symmetrically about a longitudinal centerline, defining a central region therebetween and side regions laterally outside the central region and adjacent the compressed grooves. The central region includes front, intermediate and rear central regions. The intermediate central region has a widened portion in which the separation distance is larger than in regions positioned forward and rearward thereof. Stiffness of the side regions is lower in portions laterally outside the intermediate central region than in portions laterally outside the front and rear central regions.

Abstract: The present invention provides a animal model useful in identifying a molecule controlling in a lymphocyte-specific manner migration and thus elucidating immune-related diseases and pathogenic conditions such as allergy, autoimmune diseases, GvH and graft rejections at a molecular level, or in developing a novel therapy. A nonhuman animal model such as a DOCK2 knockout mouse, in which the function to control lymphocyte migration has been deleted or suppressed, is generated by deleting DOCK2 gene on the chromosome. In this DOCK2 knockout mouse, the function of activating Rac to mediate actin cyteskeleton, the lymphocyte migration function in response to stimuli with chemokines such as SLC, SDF-1, BLC, the homing function to secondary lymphoid organs such as spleen, lymph nodes and Peyer's patches, and the function of emigrating mature thymic T cells into peripheral blood in response to stimulus with chemokine ELC are impaired, and as a result of this, immune responses are suppressed.

Abstract: This invention provides methods for the stable introduction of heterologous coding sequences into the genome of a bird and expressing the coding sequences to produce desired proteins or to alter the phenotype of the bird. The present invention provides preferred methods for introducing a transgene into the cytoplasm of avian embryonic cells by cytoplasmic microinjection. The embryo then develops into a transgenic adult capable of expressing a heterologous protein and/or capable of generating a line of transgenic birds through breeding. Synthetic vectors and gene promoters useful in the methods are also provided by the present invention, as are transgenic birds that express heterologous protein and avian eggs containing heterologous protein.

Abstract: This invention relates to an isolated nucleic acid fragment encoding a reproduction protein. The invention also relates to the construction of a chimeric gene encoding all or a portion of the reproduction protein, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the reproduction protein in a transformed host cell. The invention also provides isolated transcriptional regulatory elements and polynucleotides associated therewith.